Laekna, Inc. (HK:2105) has released an update.
Laekna, Inc. has announced the U.S. FDA’s approval for their phase III clinical trial protocol for a prostate cancer treatment regimen, LAE201, which combines two of their drug candidates. The treatment has shown promise in phase II trials, demonstrating a significant increase in median rPFS for patients with metastatic castration-resistant prostate cancer. The company aims to offer this new precision therapy as a novel treatment option for patients.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.
